Sign up for alerts
Want to make sure you never miss the latest updates?
Insights with impact
Industry Insight
Addressing Drug Resistance in Non-Small Cell Lung Cancer
Industry Insight
Scientific innovation in uveal melanoma
Industry Insight
Opportunities and challenges in oncology immunotherapy
Industry Insight
Reflections from our CEO
Industry Insight
Pancreatic cancer – our commitment to scientific advances
Industry Insight
A bold new era in global cancer drug discovery
Industry Insight
A note from our CEO
Industry Insight
Realising the potential of autotaxin therapy in cancer
Industry Insight
PI3Kδ inhibitors offer serious promise in solid tumors
Industry Insight
Emerging therapies offer hope for uveal melanoma patients
All news
Press release
iOnctura expands pipeline and receives development grant from Health Holland and KWF
Data & publication
IOA-244 is a non–ATP-competitive, highly selective, tolerable PI3K delta inhibitor that targets solid tumors and breaks immune tolerance
Press release
iOnctura awarded UK’s MHRA innovation passport for entry into innovative licensing and access pathway (ILAP)
Data & publication
Long-term safety evaluation of roginolisib (formerly IOA-244), a highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a Phase I First in Human (FIH) study
Press release
iOnctura announces publication of pioneering research describing the unique biological features of roginolisib
Data & publication
Characterization of the non-ATP competitive PI3Kδ inhibitor IOA-244 in lymphoma models: from single agent to combination screen and clinical investigation
Press release
iOnctura provides development update on first-in-class semi-allosteric PI3Kδ inhibitor program
Press release
iOnctura awarded EUR17.5 million funding from the EIC accelerator for clinical development of novel pancreatic cancer therapy
Press release
iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289
Data & publication
Safety and clinical activity of IOA-244, a highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ), in a Phase I first in human (FIH) study (study part A)
Data & publication
IOA-244 is a non-ATP-competitive, highly-selective, tolerable phosphoinositide-3-linase delta inhibitor that directly targets solid tumors and breaks immune tolerance
Data & publication
Non-ATP competitive inhibition of PI3δ with IOA-244 shows anti-lymphoma activity
Looking for media
resources?